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Megakaryocytopoiesis involves the commitment, proliferation, and differentia- 
tion of hemopoietic progenitor cells in the megakaryocyte/platelet lineage, and 
the acquisition  of functional  and  structural  properties associated with  platelet 
physiology.  Megakaryocytes contain  an  array  of alpha  granule  proteins  with 
membrane  receptors involved in platelet adhesion,  aggregation,  and secretion 
(1).  Recent  studies  (2-6)  characterizing  human  marrow  megakaryocytes have 
described a  number of platelet proteins and cytochemical activities that can be 
regarded  as  selective  markers  for  cells  of the  megakaryocytic  lineage.  Early 
immature  megakaryocytes (promegakaryoblasts)  in  normal  marrow  as  well as 
micromegakaryocytes and atypical megakaryocytes in marrow from patients with 
megakaryoblastic leukemia and  myeloproliferative  disorders  have been recog- 
nized by virtue of these markers (7-12). Moreover, the use of these markers has 
also been essential  to the  identification  and  characterization  of human  colony 
megakaryocytes grown in vitro (13-16).1 
Differentiating  hemopoietic  cells  generally  undergo  marked  structural  and 
functional changes that can be related to different ontogenetic levels (17). Studies 
of the lymphoid, myeloid, and erythroid lineages have revealed that these changes 
are  paralleled  by alterations  in  their  antigenic  profiles (18-22).  Furthermore, 
the expression of surface antigens on heterogeneous populations of morpholog- 
ically unrecognizable  hematopoietic  progenitors  has been demonstrated  using 
complement-mediated cytolytic assays in conjunction with clonogenic assays (23- 
25). Hybridoma technology, enabling the elaboration of monoclonal antibodies 
with reactivities restricted to single epitopes, has further enhanced the sensitivity 
of these bioassays. 
This  paper reports the recognition  of three  levels of human  megakaryocyte 
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differentiation based  upon  the selective expression of cell antigens  recognized 
by a  panel of monocional antibodies raised against human megakaryocytes and 
platelets.  Using  immunofluorescence, an  enzyme-linked immunosorbent  assay 
(ELISA)  2 system, and complement-mediated cytolysis, three maturational levels 
with distinct immunologic phenotypes were identified. These levels were char- 
acterized by differentiation antigens that were expressed throughout megakary- 
ocytopoiesis from the cionable megakaryocytic progenitor (megakaryocyte col- 
ony-forming unit; CFU-Mk) to either: (a) the small, mononuclear, early immature 
megakaryocyte;  (b)  the  classical,  mature  megakaryocyte with  a  polylobulated 
nucleus; or (c) the circulating blood platelet. The recognition of discrete pheno- 
typic changes in human marrow megakaryocytes first described in these studies 
provides the basis  for a  diagnostically useful classification system of the  mega- 
karyocyte/platelet lineage, and enables studies of mechanisms regulating megak- 
aryocytopoiesis in health and disease. 
Materials and Methods 
Preparation  of Human Bone Marrow Cell Suspensions.  Normal human  bone marrow 
cells were harvested from rib fragments removed at surgery or, alternatively, from bone 
marrow aspirates obtained from normal volunteers. Written consent was obtained from 
all patients before surgery in  compliance with regulations established by the  National 
Institutes of Health. Experimental protocols were approved by the Committee on Human 
Rights of New York HospitaI-Cornell Medical Center (New York). Marrow tissue was 
collected and rendered into single-cell  suspensions as described elsewhere (1,  7).  The 
medium used for this procedure was calcium- and magnesium-free Hanks' balanced salt 
solution (Gibco Laboratories, Grand Island, NY) containing 1.25 X 10  -5 M sodium citrate, 
2.52 x  10  -~ M Hepes buffer, 4.1  X 10  -8 M sodium bicarbonate, and 115 U/ml DNase I 
(all from Sigma Chemical Co., St. Louis, MO) at a final pH of 7.0 +  0.05 and 295 -+ 5 
mosM (HBSS/C). Cells were then washed twice in modified McCoy's 5-A medium (Gibco 
Laboratories) containing 2.62  x  10  -~ M  NaHCO3 (Sigma Chemical Co.) at pH  7.2  + 
0.05, 295 +  5 mosM (McCoy's 5-A). Marrow cells were fractionated by buoyant density 
centrifugation and harvested as reported (1). Gradients were generated with solutions of 
colloidal silica particles coated with polyvinyl pyrollidone (Percoll; Pharmacia Fine Chem- 
icals, Division of Pharmacia, Inc., Piscataway, NJ) in McCoy's 5-A. 
Preparation of Blood Leukocytes and Washed Platelets.  Venous blood was collected from 
normal volunteers in 0.32% sodium citrate in polypropylene test tubes.  Blood samples 
from two patients with Glanzmann's thrombasthenia and one patient with Bernard-Soulier 
disease  were  kindly provided by  Dr.  Margaret Johnson  (Wilmington  Medical  Center, 
Wilmington,  DE).  Erythrocyte-depleted suspensions  of leukocytes were  prepared  by 
sedimentation in  solutions of HBSS/C containing 3% dextran T-500 (Pharmacia Fine 
Chemicals) as previously described (7).  Washed platelets were prepared by processing 
whole citrated blood as reported elsewhere (12, 26). 
lmmunofluorescence Assays of Fixed Smears of Human Bone Marrow and Peripheral Blood 
Cells.  Suspensions of either unseparated or low density fractions of human bone marrow 
cells  (d  <  1.050  g/cm3),  erythrocyte-depleted leukocytes,  or  washed  platelets,  were 
smeared in fetal bovine serum (Flow Laboratories, Inc., Division of Flow General, Inc., 
McLean, VA) and processed for immunofluorescence staining of membrane and intracel- 
2  Abbreviations used in this paper: CFU-GEMM, multipotential progenitor of mixed colonies in 
vitro, containing neutrophililic granulocytes, erythroblasts, macrophages, and megakaryocytes;  CFU- 
Mk, BFU-E, and CFU-GM, clonable progenitor cells of megakaryocytic, erythroid, and myelomon- 
ocytic lineages, respectively; ELISA, enzyme-linked  immunosorbent assay; FITC, fluorescein isothio- 
cyanate; HBSS/C, calcium- and magnesium-free Hanks' balanced salt solution containing sodium 
citrate, Hepes buffer, sodium bicarbonate, and DNase I; KLH, keyhole limpet hemocyanin; SDS- 
PAGE, polyacrylamide  gel electrophoresis; TRITC, tetramethlrhodamine isothiocyanate. LEVENE ET AL.  459 
lular components (1, 2, 7). Cells were examined with a Leitz Ortholux II microscope (E. 
Leitz, Inc., Rockleigh, N  J) equipped with a ploem illuminator and phase contrast optics. 
Blood platelets and mature marrow megakaryocytes were identified on the basis of their 
respective  prominent morphologic features in  concurrent phase contrast microscopic 
observations (27, 28). Early immature megakaryocytes were recognized in double immu- 
nofluorescence assays by simultaneous staining of fixed smears of low density marrow 
cells with fluorochrome-conjugated monospecific antisera against human platelet glyco- 
protein IIb or Ilia. 
Preparation  of Monospecific Rabbit Antisera.  Monospecific rabbit antisera against iso- 
lated human platelet glycoproteins IIb and IIIa were kindly provided by Dr. Lawrence L. 
K.  Leung (Cornell  University Medical  College).  Heterologous rabbit  antisera against 
ovalbumin and keyhole limpet hemocyanin (KLH) were prepared and tested for specificity 
as described elsewhere (1, 7, 29, 30). Polyspecific rabbit anti-mouse Fab Ig was a generous 
gift from Dr. Howard Grey (National Jewish Hospital, Denver, CO).  IgG fractions of all 
rabbit antisera were prepared and subsequently conjugated to fluorescein (FITC) and/or 
tetramethylrhodamine (TRITC) isothiocyanate (both from BBL Microbiology Systems, 
Division of Becton, Dickinson & Co., Cockeysville, MD) as described elsewhere (1). 
Monoclonal Antibodies.  Monoclonai antibodies were raised against pure suspensions  of 
washed human platelets and low density marrow cells enriched for megakaryocytes using 
standard procedures (31).  Briefly, CB6F~ mice (The Jackson Laboratory, Bar Harbor, 
ME) were immunized twice with either platelets or low density marrow cells. Splenocytes 
from immunized mice were fused with SPO/2 mouse plasmacytoma cells in the presence 
of 35% polyethylene glycol 1540 (J. T. Baker Chemical Co., Phillipsburg, NJ). Culture 
supernatants were tested for the presence of mouse Ig and subsequently screened for 
reactivity against human platelets by solid phase ELISA. In this screening system, optimal 
platelet adherence was obtained after coating microtiter plates (Linbro Division,  Flow 
Laboratories, Inc.,  Hamden, CT) with poly-L-lysine (Sigma  Chemical Co.) Binding of 
antibody to platelets was measured spectrophotometricaUy after treatment with B-galac- 
tosidase-labeled anti-mouse Ig (BRL, Inc., Gaithersburg, MD) and O-nitrophenyl-3-I> 
galactoside (BRL, Inc.). All supernatants were also tested against smeared preparations of 
fixed platelets and marrow cells by indirect immunofluorescence  using TRITC-conjugated 
rabbit  IgG anti-mouse Fab  Ig.  After cloning by the  semisolid  agar technique in the 
presence of thioglycollate-elicited  macrophage monolayers, hybrids were reverted to liquid 
culture and their supernatants retested for reactivity and specificity against marrow and 
blood cells. To confirm reactivity against early immature and/or classical megakaryocytes, 
low density marrow cells were stained simultaneously  with a monoclonai antibody/TRITC 
rabbit anti-mouse Fab Ig and a fluoresceinated rabbit anti-platelet glycoprotein IIb or 
IIIa. The  11  monoclonal antibodies selected for their exclusive reactivity to elements 
within megakaryocyte]platelet lineage were characterized by immunoelectrophoresis as 
IgG1 isotype. 
Immunoprecipitation  and Biochemical Characterization of Platelet Membrane Antigens Rec- 
ognized by Monoclonal Antibodies.  Washed platelets were radioiodinated with 12sI (New 
England Nuclear, Boston, MA) by the tetrachloro-diphenylglycoluril  method (32). Radio- 
labeled platelets  were  solubilized with  2%  sodium dodecyl sulfate (SDS), which  was 
subsequently displaced by 1.7% Triton X-100 (Sigma Chemical Co.) in the presence of 1 
~M pepstatin (The Protein Foundation, Osaka, Japan), 2 mM phenylmethysulfonyl  fluo- 
ride, and 5 mM N-ethylamaleimide, and 10 mM EGTA (all from Sigma Chemical Co.) to 
minimize proteolysis. Platelet protein lysates  were subjected to solid phase immunoad- 
sorption with protein A-Sepharose CL-4B beads (Pharmacia Fine Chemicals) coated with 
various monoclonal antibodies (33). Specifically bound protein was eluted with 2% SDS 
and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  under reducing 
and nonreducing conditions and autoradiography (34, 35). 
Complement-mediated Cytolytic Assay.  Unseparated marrow cells were washed twice in 
McCoy's 5-A  medium. Aliquots of 6  ×  106 cells were then incubated with 375  /zl of 
ammonium sulfate-precipitated mouse monoclonal antibody preparations for 30 min at 
room temperature, and subsequently washed twice in McCoy's 5-A. Antibody-treated cells 460  PHENOTYPES  OF  DIFFERENTIATING  MEGAKARYOCYTES 
were then incubated with 375 tA of a second antibody, a rabbit IgM anti-mouse IgG, at 
room temperature for 30 min, and washed twice in McCoy's 5-A medium. Cells  were 
then resuspended in 375 ~1 undiluted oxidized normal human AB Rh  D+ serum, used as 
source of complement, and incubated at 37°C for 30 rain (36-38). After two washes  in 
McCoy's 5-A medium, cells were plated in culture as indicated below. Rabbit IgM anti- 
mouse IgG was prepared by short immunization of New Zealand White rabbits (Hazelton- 
Dutchland, Denver, PA) with mouse IgG in complete Freund's adjuvant (Gibco Labora- 
tories). Mouse IgG was prepared from DBA/2A (The Jackson Laboratory) serum, first 
precipitated  in  ammonium  sulfate,  followed  by  DE-52  chromatography  in  0.03  M 
NAH~PO4 at pH 8.3. At day 21 of immunization, rabbits were bled by cardiac puncture 
and serum was precipitated with 50%-saturated ammonium sulfate. The identity, class, 
and activity of this antibody preparation was confirmed by immunoelectrophoresis. 
Growth of CFU-Mk in Semisolid Agar.  Untreated and treated cells or freshly isolated 
marrow cells were plated for growth of  CFU-Mk using a semisolid agar system, as described 
in more detail elsewhereJ Briefly, cell suspensions of 2 ×  105 nucleated marrow cells/ml 
or cells remaining in this volume after treatment were cultured in a supplemented McCoy's 
5-A medium containing 0.26% Bacto-Agar (Difco Laboratories, Inc., Detroit, MI), 17.4% 
horse serum (Flow Laboratories, Inc.), and 4.4% medium conditioned by the Mo cell line 
(Dr.  David  Golde, UCLA  School of Medicine,  Los Angeles,  CA).  The supplemented 
McCoy's 5-A contained 9.3 x  10  -2 M sodium pyruvate, 0.74% 50× minimum essential 
medium (MEM)-essential amino acid mixture, 0.56%  100×  MEM-nonessential amino 
acid mixture, 0.56%  100×  MEM-vitamin mixture,  1.12 ×  10  -s M L-glutamine,  1.15 × 
10  -7  M  asparagine,  7.59  ×  10  -s  M  serine (all  from Gibco Laboratories Co.),  0.93% 
penicillin (10,000 U/ml)-streptomycin (10,000 U/ml) mixture (Microbiological Associates, 
Walkersviile, MD), 3.53 ×  10  -~ M NaHCO, and 3.23 ×  10  -s M Hepes buffer (both from 
Sigma Chemical Co.). Growth of megakaryocytic colonies was monitored by staining fixed 
colony cells  by flooding the  entire culture  dish  with  either  heterologous antisera  or 
monoclonal antibody preparations specific for platelet glycoprotein IIb or IIIa. Colony 
megakaryocytes were scored on day 7 or 8 by examining stained colonies in situ with a 
Leitz Diavert phase contrast, inverted microscope equipped with a ploem illuminator and 
optics for fluorescent microscopy (E. Leitz, Inc.). 
Growth of CFU-GEMM and BFU-E.  Growth of muitipotential hemopoietic progenitors 
(granulocyte, erythroblast, macrophage, and megakaryocyte colony-forming units; CFU- 
GEMM) and erythroid bursts (erythroid burst-forming unit; BFU-E) was conducted and 
scored as previously described (39, 40). Unseparated marrow cells were plated in Iscove's 
modified Dulbecco's medium (Gibco Laboratories) containing 1% methylcellulose (Calla- 
ban Chemical Co., Palmyra, NJ), 30% fetal bovine serum (Biofluids, Inc., Rockville, MD), 
5% medium conditioned by leukocytes from patients with hemachromatosis in the pres- 
ence of 1% phytohemagglutanin (HA-15; Welcome Reagents, Ltd., Welcome Research 
Laboratories, Detroit, MI), 5 ×  10  -5 M 2-mercaptoethanol (Sigma Chemical Co.), 1 U of 
Step III preparation of sheep plasma erythropoietin (Connaught Labs, Ltd., Wiliowdale, 
Ontario, Canada), and 0.2 mM Heroin (Eastman Kodak Co., Rochester, NY) (41, 42). 
Cultures were incubated at 37°C in a humidified atmosphere flushed with 5% CO, in air. 
Colonies were scored with an inverted microscope after 14 d of incubation and identified 
further after picking out colonies with a fine pipette, transferring them to glass slides, and 
staining with benzidine and/or Wright's-Giemsa to confirm their mixed nature. Mixed 
colonies usually contained erythroid, granulocytic, and monocytic cells, and sometimes 
megakaryocytes. BFU-E were scored from these same plates. 
Growth of CFU-GM.  The colony assay  for granuiocyte macrophage colony-forming 
units (CFU-GM) was performed as described previously (43). Marrow cells were plated in 
McCoy's 5-A containing 10% heat-inactivated bovine serum, 0.3% agar, and 10% condi- 
tioned  medium  obtained  from  either  the  growth  of giant  cell  tumor  (GCT) (Gibco 
Laboratories) or 5637 cell line (44, 45). To monitor the effects of the cytolytic assay on 
the two subpopulations of CFU-GM, cultures were incubated at 37°C for 7 and 14 d, at 
which times they were scored for cluster (3-50 cells per aggregate) and colony (>50 cells 
per aggregate) formation as described (42, 43). LEVENE ET AL.  461 
Results 
Phenotypic  Changes  Associated  With  the  Ontogeny  of  Megakaryocytes/Plate- 
lets.  Studies  of phenotypic  changes  in  differentiating  megakaryocytes were 
conducted  using a  panel  of monoclonal  antibodies  generated  against  human 
megakaryocytes and platelets. Different levels of megakaryocyte maturation were 
recognized based  upon  the distribution  of specific cell antigens detected by a 
panel of 11  monoclonal antibodies.  These antibodies reacted exclusively with 
megakaryocytes and  platelets  in  indirect  immunofluorescence assays of fixed 
smears of marrow and blood cell preparations obtained from 25 normal subjects. 
Furthermore, reactivity against platelets was corroborated by a crosslinked, solid 
phase ELISA system. Based upon their ability to recognize cell antigens associated 
with distinct levels of differentiation, monocional antibodies were operationally 
categorized  into  three  groups  (Table  I).  Six  different  monoclonal  antibody 
preparations  categorized  in  group  A  recognized  epitopes  on  early  immature 
megakaryocytes, but not on mature megakaryocytes or platelets. Group B mono- 
clonal antibody MkB-1  recognized  an  antigenic determinant  expressed  by all 
early and mature megakaryocytes, but not by platelets. This unique pattern of 
reactivity is demonstrated in  Fig.  1,  which depicts isolated marrow megakary- 
ocytes mixed with washed platelets and costained with MkB-1  monoclonal anti- 
body  by  indirect  immunofluorescence  (Fig.  1,  a  and  b).  Overlying  platelets 
partially obscure cytologic detail in phase contrast counterpart micrographs (Fig. 
1,  a'  and b').  Four monoclonal antibodies classified in group C  reacted to all 
early and mature megakaryocytes as well as platelets, Mature marrow megakar- 
yocytes and blood platelets were readily identified on the basis of their respective 
prominent morphologic features. Early immature megakaryocytes were recog- 
nized in double immunofluorescence assays by simultaneous staining of marrow 
cells with fluorochrome-conjugated monospecific antisera against human platelet 
glycoproteins IIb and IIIa. The specificity of fluorescence staining was controlled 
by incubating cells directly with the fluorochrome-conjugated rabbit anti-mouse 
TABLE  I 
Distribution Profile in Marrow and Blood Cells of Antigens Detected by Monoclonal Antibodies 
Raised Against Megakaryocytes and Platelets 
Monoclonal antibodies  Immunogen* 
Cells stained by immunofluorescence* 
Immature  Mature  Other cell  mega-  megakary- Platelets 
karyocytes  ocytes  types 
Group A (6)e  Megakaryocytes  +  -  -  - 
Group B (1)  Megakaryocytes  +  +  -  - 
Group C (4)  Platelets  +  +  +  - 
* Monoclonal antibodies were generated against megakaryocyte-enriched,  low density marrow cells 
or washed blood platelets. 
* Cells were stained by indirect immunofluorescence  with monoclonal  antibody followed  by TRITC 
rabbit anti-mouse Fab Ig. Immature megakaryocytes  were identified as mononuclear lymphoid- 
like cells also bearing platelet glycoprotein Ilb-IIIa. Other cell types included unstained marrow 
and blood cells, which presumably belong to the pool of mature cells, and are precursors of the 
myelomoncytic,  erythroid, and lymphoid series. 
! Number of different monoclonal  antibodies in functional grouping. 462  PHENOTYPES  OF  DIFFERENTIATING  MEGAKARYOCYTES 
FIGURE  1.  Isolated human marrow megakaryocytes and blood platelets costained by immu- 
nofluorescence  with  MkB-1  monoclonal  antibody.  Washed  platelets  were  mixed with  low 
density marrow cells, smeared, methanol fixed, and (a and b) stained by indirect immunoflu- 
orescence with monoclonal antibody MkB-1, followed by TRITC rabbit anti-mouse Fab Ig. 
(a',b') Same field under phase contrast microscopy. X 938. 
Fab Ig antisera and by preincubating cells with normal mouse IgG or a nonreac- 
tive hybridoma secretory IgG. Moreover, no change in the reactivity profile of 
the different monoclonal antibodies  to  various cell  types was  observed when 
reagents were tested at increased concentrations. 
Expression  of Megakaryocytic Differentiation  Antigens  by  Colony Megakaryocytes 
Grown In Vitro.  The expression of various epitopes recognized by the panel of 
monoclonal antibodies was investigated in colony megakaryocytes  grown in agar. 
In  a  series  of double  immunofluorescence assays,  colony  cells  were  stained 
sequentially in  situ  with  the different monoclonal antibodies  and  antiplatelet 
glycoprotein IIb antiserum was used to identify megakaryocytic cells.  All mega- 
karyocytic colony cells harvested at day 7 or 8 were intensely stained by groups 
A, B, and C monocional antibodies. A representative picture of a typical human LEVENE ET AL.  463 
megakaryocytic colony grown from  unseparated  marrow  in  the semisolid agar 
system is depicted in  Fig.  2.  The colony was harvested at day 7,  gently dried, 
fixed, agarase-treated,  and stained by indirect immunofluorescence with mono- 
clonal  antibody  PC-1.  In  parallel  controls  for  the  specificity  of the  indirect 
immunofluorescence system, cultures were incubated with only the second anti- 
body preparation or with a nonrelated antibody directly conjugated to a fluoro- 
chrome.  Colony cells were not stained by either the TRITC rabbit anti-mouse 
Fab  Ig  reagent  or  the  FITC  rabbit  IgG  anti-KLH  antiserum.  Additionally, 
granulocyte-macrophage  colony cells were not stained by group C  monoclonal 
antibody PC-1. 
Distribution  of Megakaryocytic  Differentiation  Antigens  on  CFU-Mk  and  Other 
Clonable  Hematopoietic Progenitors.  Expression of cellular antigens  was investi- 
gated on clonable hemopoietic progenitors  using a  complement-mediated cyto- 
lytic  assay.  To  ensure  maximum  complement  fixation  and  to  enhance  the 
sensitivity of the cytolytic assay, cells were preincubated with a rabbit IgM anti- 
mouse IgG preparation before the addition of complement (46). Oxidized human 
AB Rh  D+ serum prepared by iodination was used as the source of complement 
(37).  The  reactivity  of the  various  monoclonal  antibodies  against  CFU-Mk is 
expressed as the percent inhibition of colony growth on Table II. These values 
represent the means resulting from the comparison of quadruplicate experimen- 
tal  conditions  to  quadruplicate  untreated  controls.  When  mean  values  were 
derived  from  multiple  experiments,  the  number  of experiments  performed  is 
indicated  in parentheses.  Monoclonal antibodies from group A,  which reacted 
against early megakaryocytes but not mature megakaryocytes or platelets, exhib- 
ited 64-100%  inhibition  of colony growth.  Monoclonal antibody MkB-1  from 
group  B,  which  reacted  against  early  and  mature  megakaryocytes  but  not 
platelets,  inhibited  63%  of colony  growth.  Group  C  monoclonal  antibodies, 
which reacted against early and mature megakaryocytes as well as platelets, had 
inhibitory effects of 66-100%.  It is noteworthy that  when various monoclonal 
FIGURE 2.  Immunofluorescence  staining of human megakaryocytic  colony  harvested at day 
7. Culture was dried, methanol fixed, agarase treated, and (a) stained by indirect immunoflu- 
orescence with monoclonal antibody PC-l, followed  by TRITC rabbit anti-mouse Fab Ig. (b) 
Same feld under phase contrast microscopy.  × 375. 464  PHENOTYPES  OF  DIFFERENTIATING MEGAKARYOCYTES 
TABLE  II 
Expression of Membrane Antigens on CFU-Mk Detected by 
Complement-mediated Cytolysis 
Pretreatment of marrow cells 
Percent inhibition of 
Monoclonal  Rabbit IgM  Comple-  CFU-Mk growth  ~t 
antibody  anti-mouse  lgG*  ment 
Group A 
MkA-1  +  +  97 ± 4  (4) 
MkA-1  -  +  42 ± 0 
MkA-2  +  +  82 ± 0 
MkA-3  +  +  94 + 9 
MkA-4  +  +  94 + 9 
MkA-5  +  +  100 + 0 
MkA-6  +  +  64 +  17 
Group B 
MkB-1  +  +  63 ±  11 (4) 
MkB-1  -  +  31 +  16 
Group C 
PC-1  +  +  77 ±  13 (5) 
PC-1  -  +  51 ±  13 (2) 
PC-2  +  +  88 ±  9  (4) 
PC-2  -  +  52 ± 6 
PC-3  +  +  66 ± 4 
PC-4  +  +  100 -4- 0 
* Addition (+) or omission (-) of designated component. 
* The mean __. SD of percent inhibition was determined from comparison 
of replicate treated samples with replicate controls not treated with any 
antibody or complement. Parallel controls of samples treated with var- 
ious monoclonal antibody preparations, rabbit IgM, or complement, had 
inhibitory effects <6%.  Megakaryocytic colonies grown in agar were 
identified by immunofluorescence using anti-platelet glycoprotein IIb/ 
Illa antisera. Number of experiments is indicated in parentheses. 
antibody preparations  were tested by the cytolytic assay without the rabbit IgM 
complement  fixation amplification step, substantially less inhibition was detected 
(Table II). 
Clonable progenitors cells of other hemopoietic lineages were also studied for 
the expression of the various antigens recognized by the monoclonal antibodies. 
For this purpose,  marrow  cells were  processed by the cytolytic assay described 
above and then cultured, concurrently, for the growth of CFU-GEMM,  BFU-E, 
the  bipotential  granulocyte-macrophage  progenitor  (CFU-GM),  and  CFU-Mk 
cells.  Two  distinct subpopulations  of CFU-GM  were  recognized,  one  forming 
colonies  in  7  d  and  the  second  forming  colonies  in  14  d.  Additionally,  an 
operational distinction was made between  GM clusters (3-50  cells) and colonies 
(>50 cells) (43).  The  effects of PC-2 antibody from group C  on colony formation LEVENEET  AL.  465 
by CFU-GM,  BFU-E,  CFU-GEMM,  and CFU-Mk was assessed  in a  series  of 
multilineage cytolytic assays  (Table III).  In three experiments, the number of 
colonies scored in entire plates is expressed as the mean of replicate cultures. 
Percent changes represent comparisons between experimental and control con- 
ditions, and reflect reduction or augmentation of colony formation. As shown, 
monoclonal antibody PC-2 inhibited 87% (P <  0.001) of CFU-Mk growth as well 
as 27% (P <  0.03) of BFU-E formation, but showed no significant inhibition of 
mixed GEMM  colonies or granulocyte-macrophage colonies or  clusters.  The 
probability  of significant differences between  samples was  determined using 
Student's t test (47). In similar multilineage assays, monoclonal antibodies MkA- 
i, MkB-1  and PC-1  inhibited 97% (P <  0.001), 58% (P <  0.05), and 64% (P < 
0.01) of megakaryocytic colony formation, respectively (Table IV). Additionally, 
MkA-1,  MkB-1,  and  PC-1  exhibited  no  significant  inhibition  (P  >  0.05)  of 
GEMM, erythroid burst, or GM colony and/or cluster growth. 
Immunochemical Characterization of Group C Monoclonal Antibodies.  Cell anti- 
gens recognized by group C antibodies were characterized by autoradiographic 
analysis of immunoprecipitated, radiolabeled platelet membrane proteins after 
SDS-PAGE. Autoradiograms ofeluants obtained from immunobeads coated with 
PC-l, PC-3, and PC-4 are depicted in Fig. 3. Under nonreducing conditions, all 
three monoclonal antibodies precipitated proteins with approximate molecular 
weights of 135,000 and 95,000. After reduction, these antigenic moieties under- 
went a shift in their electrophoretic mobilities to 125,000 and 115,000 mol wt. 
The electrophoretic behavior of immunoisolated proteins with respect to molec- 
ular weights and shift in mobility after reduction is comparable to that describe 
TABLE  III 
Detection of Membrane Antigen Recognized by Group C Monoclonal  Antibody PC-2 on CFU- 
Mk, CFU-GM, BFU-E, and CFU-GEMM by Complement-mediated Cytolysis 
Pretreatment * of 
cells  Number of colonies scored 
CFU-GM  ~ 
Exp. 
No.  Day 7  Day 14  CFU-GEMM 
PC-2  IgM  C  CFU-Mk  BFU-E 
Colonies  Colonies 
Colonies  Colonies  +  clus- 
+ clusters 
ters 
1  -  +  +  10.04-0.0  36+4  116:t:5  323=2  59=1:2  53:t:3  2.0±0.7 
+  +  +  1.5 3= 0.5  39 ±  6  102 3= 12  30 :t= I  59 4- 1  35 3= 7  2.3 =t: 0.5 
2  -  +  +  7.0=t:0.0  44±9  122+6  26+4  ND  584-4  6.8=1=1.3 
+  +  +  1.0+0.8  41=1=5  117±9  23=1:5  ND  47:t:7  4.0+1.4 
3  -  +  +  ND  34 ±  2  92 :t: 6  17 =1:2  25 3= 2  46 ::1:6  3.8 +  0.8 
+  +  +  ND  37 +  I  91  +  1  20 +  2  27 ±  4  33 +  3  3.3 +  1.0 
Percent change:  -87.0:1:8.6!  +3:t:9  -6=1:6  -12:t:6  -4:t:6  -27:t=8  -13.04-16 
Data represent values  :I:  SD observed for  quadruplicate cultures;  ND, not done. 
* Before plating,  marrow cells  were pretreated, sequentially,  with monoclonal antibody PC-2, rabbit  IgM anti-mouse Fab Ig (IgM), 
and  human complement (C). 
CFU-GM  colonies  were aggregates of  >50 cells;  clusters  were aggregates of  $-50 ceils. 
l  Mean percent change :I: I SD observed for all  experiments; for CFU-Mk, this  value also  reflects  observations reported in Table II. 
P values  of  percent change of  CFU-Mk and BFU-E colony formation were <0.001 and <0.3, respectively.  P values  for  other colony 
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TABLE IV 
Detection of Membrane Antigens Recognized by Groups A, B, and C Monoclonal Antibodies on 
CFU-Mk, CFU-GM, BFU-E, and CFU-GEMM by Complement-mediated Cytolysis 
Percent change of colony formation* 
CFU-GM*  Monoclo- 
nal  Day 7  Day 14  CFU- 
antibodies  CFU-Mk  BFU-E  GEMM 
Colonies  Colonies  Colonies  Colonies  +  clusters  +  clusters 
MkA-1  -97__.4  -6+13  +4+29  -13±17  -21+13  -15±11  -21±6 
MkB-1  -58±11  -21±20  -19±17  -9+10  +1±4  -16±4  -23±20 
PC-1  -64±  12  -6±8  -7±  13  -20±3  -10±3  -17±4  -22±8 
Data represent mean percent change +  SD from at least three experiments. P  values of percent 
change of CFU-Mk colony formation were: MkA-1, ~0.001; MkB-I, _<0.05; PC-l, _<0.01. P values 
of percent change for other colony systems were >0,05. 
* Ranges of mean colony growth for each culture system: CFU-Mk, 7-18; CFU-GM day-7 colonies, 
22-44; day-7 colonies +  clusters, 92-122;  CFU-GM day-14 colonies,  17-34;  day-14 colonies + 
clusters, 25-64; BFU-E, 24-62; CFU-GEMM, 20-7. 
* CFU-GM colonies were aggregates of >50 cells; CFU-GM clusters were aggregates of 3-50 cells. 
for glycoproteins IIb and  Ilia  (48).  To  further investigate the nature of the 
antigen recognized by PC-l, studies were conducted by immunofluorescence on 
platelets from patients  with  restricted molecular defects.  PC-1  failed to  stain 
platelets from two patients with Glanzmann's thrombasthemia that are deficient 
in glycoproteins IIb and IIIa. On the other hand, the same antibody stained all 
platelets from a patient with Bernard-Soulier disease who lacks glycoprotein Ib. 
Discussion 
Three levels of maturation with distinct immunologic phenotypes were rec- 
ognized in the megakaryocyte/platelet lineage. The expression of these cellular 
epitopes  was  regarded  as  a  differentiation  marker  for  immature/progenitor 
megakaryocytes, mature megakaryocytes, and platelets. The antigenic modula- 
tion underlying the phenotypic changes was characterized by the unidirectional 
suppression or loss of expression throughout maturation. These differentiation 
antigens were detected by a  panel of 11  monoclonal antibodies, raised against 
marrow megakaryocytes and blood platelets, which were operationally catego- 
rized into three groups, based upon their selective reactivities. Six monoclonal 
antibodies in  group  A  recognized epitopes expressed on  the vast majority of 
CFU-Mk, on all in vitro grown colony megakaryocytes, and all immature marrow 
megakaryocytes. This  antigenic determinant,  however, was not  expressed on 
either mature marrow megakaryocytes or platelets. Furthermore, the group A 
antibody MkA-1 recognized an epitope that is apparently restricted to the early 
megakaryocytic compartment and was not detected on clonable progenitors of 
other hemopoietic lineages. The group  B monoclonal antibody MkB-1  recog- 
nized an antigenic determinant that is expressed only within the megakaryocytic 
lineage, by a  proportion of CFU-Mk, all  immature and mature marrow mega- 
karyocytes, and on in vitro grown colony megakaryocytes. However, this epitope 
is  lost  or suppressed during terminal differentiation and is  not detectable on LEVENE ET AL.  467 
FIGURE 3.  Autoradiogram of immunoprecipitated, radiolabeled platelet membrane proteins 
after SDS-PAGE. Washed platelets were radioiodinated, solubilized,  and extracts immunoad- 
sorbed with protein  A-Sepharose CL-4B beads coated with different group C monoclonal 
antibodies. Molecular markers are indicated in kilodaltons on the right: myosin, 200 kD; 
phospholipase B, 92.5 kD; bovine serum albumin, 69 kD; ovalbumin, 46 kD. Eluants from 
immunobeads coupled to PC-1 (A and A'), PC-3 (B and B'), and PC-4 (C and C') were analyzed 
by 7.5% SDS-PAGE  under nonreducing (A-C) and reducing (A'-C') conditions. 
platelets.  The  four monoclonal antibodies  categorized in  group  C  recognized 
epitopes expressed on CFU-Mk, in vitro grown colony megakaryocytes, immature 
and  mature  marrow  megakaryocytes, as  well as  blood platelets.  Furthermore, 
the group C  monoclonal antibody PC-1  had no demonstrable reactivity against 
any other type of marrow or blood cell, including the clonable progenitors CFU- 
GEMM, BFU-E and CFU-GM. Consequently, PC-1  may be considered a  lineage- 
specific marker  for the  entire  megakaryocyte/platelet series.  Within  the  same 
group, PC-2 showed slight significant reactivity against BFU-E, but not against 
their mature progeny. 
From these studies, the reduction of colony growth was interpreted to reflect 
the expression of the different epitopes on the clonable progenitors as assayed 
by cytotoxicity. Alternatively, it is possible that the reduction of colony formation 
is  secondary  to  the  elimination  of needed  accessory  cells.  Nevertheless,  this 
appears unlikely since these antibodies do not recognize known accessory cells, 468  PHENOTYPES OF  DIFFERENTIATING MEGAKARYOCYTES 
such as T  or B lymphocytes, or monocytes or any other hematopoietic cells that 
are not in the megakaryocyte/platelet series. 
Platelet glycoprotein IIb/IIIa contained the epitopes recognized by monoclo- 
nal  antibodies  PC-l,  PC-3,  and  PC-4.  This  was  demonstrated  by  SDS-PAGE 
analysis  of radioiodinated  platelet  proteins  immunoprecipitated  by  these  re- 
agents. Additionally, in immunofluorescence studies, PC-1 did not stain platelets 
from two patients with  Glanzmann's  thrombasthenia deficient in glycoprotein 
IIb/IIIa but readily stained platelets from a patient with Bernard Soulier disease 
lacking glycoprotein Ib. Collectively, these results demonstrate that the antigenic 
determinant  recognized  by  the  monoclonal  antibody  PC-1  is  located  on  the 
platelet glycoprotein IIb/IIIa complex (49). This is the first report documenting 
the expression of platelet glycoprotein IIb/IIIa at  the level of the committed 
megakaryocyte progenitor.  Previously (7, 8), this antigen has been detected by 
immunofluorescence in all  mature and early immature megakaryocytes, using 
both  heterologous and  monoclonal  antibody  preparations.  Furthermore,  evi- 
dence presented here strengthens the notion that platelet glycoprotein IIb/IIIa 
is a megakaryocyte/platelet lineage-specific antigen. 
Thus far, we have been unable to immunoisolate the PC-2 and MKB-1 antigens. 
Difficulties  in  immunoprecipitation of these  membrane  antigens  may  be  ex- 
plained by their nature (glycolipids/lipids) or by poor radiolabeling due to the 
low frequency of tyrosine in the peptides. Because of the restricted reactivity of 
group A  monoclonai antibodies to megakaryocyte precursors and progenitors 
that occur at extremely low frequency in normal marrow,  marrow and blood 
cells from leukemic patients as well as established cell lines are being screened 
by flow cytometry, with the expectation that the antigens recognized by these 
antibodies may be expressed at detectable densities on some of these cells.  At 
this point group A  and  B  monoclonal antibodies  have shown no reactivity  to 
leukocytes from 29 patients with various myelo-lymphoproliferative disorders or 
to  cells  from  a  subclone  of the  K-562  cell  line that  expresses  a  multilineage 
phenotype (R. Levene, E. Rabellino, and B. Koziner, unpublished observations). 
Group C monoclonal antibody PC-2's partial reactivity against BFU-E but not 
its progeny may provide insight into the complex hierarchal interrelationships 
operating at early levels of hematopoiesis. Various reports have described puta- 
tive  intimate  associations  between  erythropoiesis  and  megakaryocytopoiesis. 
Mixed erythro-megakaryocytic colonies have been grown in vitro from mouse 
bone marrow cells in various systems (50, 51). The clonal origin of these "mega- 
erythro bursts" from primitive biopotential progenitors has been established by 
cytogenetic analysis (52). Similar phenotypic relationships between human gran- 
ulocytes, blood monocytes, and their common bipotential progenitor, CFU-GM, 
have been detected using monoclonal antibodies.  Antigens recognized by 4F2 
and MY-7 are expressed on CFU-GM and monocytes (53,  54). Conversely, the 
antigen detected by MY-1  is recognized on CFU-GM and granulocytes, but not 
on monocytes (55).  Future studies characterizing  PC-2 ÷ BFU-E  may elucidate 
the exact nature of this interrelationship. 
In general, differentiating hemopoietic cells undergo structural and functional 
changes that are paralleled by alterations in their antigenic profiles (17). These 
phenotypic changes  may  involve  modifications of membrane  glycoprotein or LEVENE ET AL.  469 
glycolipid constituents  affecting  either  the  acquisition  of new  antigens,  the 
exposure of cryptic antigens, or conversely, the loss or sequestration of certain 
antigenic sites (56). These patterns of antigenic modulation have been described 
for  the  human  lymphocytic,  myelomonocytic, and  erythroid  series  (21-25). 
Furthermore, antigenically distinct subpopulations of precursors within each of 
these lineages have been recognized (22, 44, 57-60). 
Previously, analogous phenotypic characterization of the human megakaryocy- 
tic compartment has been limited. Staging of human megakaryocyte maturation 
traditionally has been achieved using morphological and/or ultrastructural cri- 
teria in conjunction with ploidy values (61-63). Assays for cytochemical markers, 
such as acid phosphatase isozyme analysis have also been used to establish indices 
of megakaryocyte maturation (64).  More recently, analogous studies have been 
performed using monoclonal antibodies raised against human platelets as well as 
a crossreactive monoclonal antibody raised against a human schwannoma tumor 
or monocytic cells (8,  65-67).  However, no definitive analysis  of the earliest 
developmental  compartments  using  specific  megakaryocytic  differentiation 
markers has been described. 
The  panel  of monoclonal antibodies  described in this  communication will 
certainly facilitate a more accurate and rapid staging of megakaryocytes  in normal 
and  pathologic marrows.  Future  studies  focused on  multiparameter analyses 
using these maturational markers of the different ontogenetic levels will facilitate 
recognition and description of patterns of differentiation in vivo and in vitro. 
Summary 
Human  megakaryocytes  were  studied  for  phenotypic  changes occurring 
throughout differentiation using a panel of monoclonal antibodies raised against 
marrow megakaryocytes and blood platelets. 1  ]  monoclonal antibody  prepara- 
tions  were  selected  for  restricted  specificity  against  megakaryocytes and/or 
platelets after screening by immunofluorescence, complement-mediated cyto- 
lysis, and solid phase enzyme-linked immunosorbent assay.  The expression of 
the cellular epitopes recognized by these reagents enabled the identification of 
three levels of megakaryocyte maturation characterized by distinct immunologic 
phenotypes, l~ased upon their reactivities against megakaryocytic cells at different 
ontogenetic levels, monoclonal antibodies were operationally categorized into 
three groups.  Group  A  consisted of six  different monoclonal antibodies that 
recognized antigens on the colony-forming unit-megakaryocyte (CFU-Mk), in 
vitro  grown  colony megakaryocytes, and  early immature marrow megakary- 
ocytes,  only,  and  did  not  detect  their  respective  epitopes  on  either  mature 
megakaryocytes or platelets.  A  monoclonal antibody categorized in group B 
detected a  cell antigen expressed by megakaryocytic cells at  all  maturational 
levels, but which is lost or suppressed during terminal differentiation and is not 
expressed  on  blood  platelets.  Group  C  included  four  different  monoclonal 
antibodies raised against  platelets  that recognized antigenic determinants ex- 
pressed on the CFU-Mk, colony megakaryocytes, early and mature megakary- 
ocytes, and platelets. Three group C  monoclonal antibodies (PC-l,  PC-3, and 
PC-4)  were specific for platelet glycoprotein IIb/IIIa.  Additionally, group C 
monoclonal antibody PC-2 was unique in that it showed partial reactivity against 470  PHENOTYPES  OF  DIFFERENTIATING  MEGAKARYOCYTES 
the cionable progenitor for the erythroid series (BFU-E). Recognition of discrete 
phenotypic changes in differentiating megakaryocytes will enable multiparameter 
analyses of these cells as well as the study of factors regulating the dynamics of 
megakaryocytopoiesis in health and disease. 
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